Gnanasakthy A, Russo J, Gnanasakthy K, Harris N, Castro C. A review of patient-reported outcome assessments in registration trials of FDA-approved new oncology drugs (2014-2018). Contemp Clin Trials. 2022 Sep;120:106860. doi: 10.1016/j.cct.2022.106860
Anderson C, Smitherman AB, Meernik C, Edwards TP, Deal AM, Cannizzaro N, Baggett CD, Chao C, Nichols HB. Patient/provider discussions about clinical trial participation and reasons for nonparticipation among adolescent and young adult women with cancer. J Adolesc Young Adul. 2020 Feb;9(1):41-6. doi: 10.1089/jayao.2019.0078
Butler AM, Layton JB, Krueger WS, Kshirsager AV, McGrath LJ. Assessing residual bias in estimating influenza vaccine effectiveness: comparison of high-dose versus standard-dose vaccines. Med Care. 2019 Jan;57(1):73-8. doi: 10.1097/MLR.0000000000001018
Ling W, Nadipelli VR, Ronquest N, Albright VA, Aldridge AP, Learned SM, Mehra V, Heidbreder C. Remission from chronic opioid use-studying environmental and socio-economic factors on recovery (RECOVER): study design and participant characteristics. Contemp Clin Trials. 2019 Jan;76:93-103. doi: 10.1016/j.cct.2018.11.015
Vodicka E, Kim K, Devine EB, Gnanasakthy A, Scoggins JF, Patrick DL. Inclusion of patient-reported outcome measures in registered clinical trials: evidence from ClinicalTrials.gov (2007-2013). Contemp Clin Trials. 2015 Apr 18;43:1-9. doi: 10.1016/j.cct.2015.04.004
Garcia-Albeniz X, Logan RW, Schrag D, Hernan MA. Evaluation of the duplication of staging CT scans for localized colon cancer in a Medicare population. Med Care. 2014 Nov;52(11):963-8. doi: 10.1097/MLR.0000000000000231
Wheeler SB, Kohler RE, Goyal RK, Lich KH, Lin CC, Moore A, Smith TW, Melvin CL, Reeder-Hayes K, Domino ME. Is medical home enrollment associated with receipt of guideline-concordant follow-up care among low-income breast cancer survivors? Med Care. 2013 Jun;51(6):494-502.
Gnanasakthy A, DeMuro C, Boulton C. Integration of patient-reported outcomes in multiregional confirmatory clinical trials. Contemp Clin Trials. 2013 May 1;35(1):62-9.
Hareendran A, Gnanasakthy A, Winnette RM, Revicki D. Capturing patients' perspectives of treatment in clinical trials/drug development. Contemp Clin Trials. 2012 Jan;33(1):23-8.
Stull DE, Wiklund I, Gale R, Capkun-Niggli G, Houghton K, Jones P. Application of latent growth and growth mixture modeling to identify and characterize differential responders to treatment for COPD. Contemp Clin Trials. 2011 Nov 1;32(6):818-28.
Mease PJ, Clauw DJ, Christensen R, Crofford LJ, Gendreau RM, Martin SA. Toward development of a fibromyalgia responder index and disease activity score: oMERACT module update. J Rheumatol. 2011 Jul 1;38(7):1487-95.
Choy EH, Arnold LM, Clauw DJ, Crofford LJ, Glass JM, Simon LS, Martin SA, Strand CV, Williams DA, Mease PJ. Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome. J Rheumatol. 2009 Oct 1;36(10):2330-4.
Mease P, Arnold LM, Choy EH, Clauw DJ, Crofford LJ, Glass JM, Martin SA, Morea J, Simon L, Strand CV, Williams DA. Fibromyalgia syndrome module at OMERACT 9: domain construct. J Rheumatol. 2009 Oct 1;36(10):2318-29.
Mease PJ, Russell IJ, Arnold LM, Florian H, Young JP, Martin SA, Sharma U. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol. 2008 Mar;35(3):502-14.
Schneeweiss S, Patrick AR, Sturmer T, Brookhart MA, Avorn J, Maclure M, Rothman KJ, Glynn RJ. Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care. 2007 Oct 1;45(10 - Suppl 2):S131-42.
Sturmer T, Glynn RJ, Rothman KJ, Avorn J, Schneeweiss S. Adjustments for unmeasured confounders in pharmacoepidemiologic database studies using external information. Med Care. 2007 Oct 1;45(10 - Suppl 2):S158-65.
Mease P, Arnold LM, Bennett R, Boonen A, Buskila D, Carville S, Chappell A, Choy E, Clauw D, Dadabhoy D, Gendreau M, Goldenberg D, Littlejohn G, Martin SA. OMERACT 8 workshop: fibromyalgia syndrome. J Rheumatol. 2007 Jun;34(6):1415-25.
Bray JW, Zarkin GA, Davis KL, Mitra D, Higgins-Biddle JC, Babor TF. The effect of screening and brief intervention for risky drinking on health care utilization in managed care organizations. Med Care. 2007 Feb 28;45(2):177-82.
Lafata JE, Pladevall-Vila M, Divine G, Ayoub M, Philbin EF. Are there race/ethnicity differences in outpatient congestive heart failure management, hospital use, and mortality among an insured population? Med Care. 2004 Jul;42(7):680-9.
Neville C, Whalley D, McKenna SP, Le Comte M, Fortin PR. Adaptation and validation of the Rheumatoid Arthritis Quality of Life Scale for use in Canada. J Rheumatol. 2001 Jul 1;28(7):1505-10.
Harris-Kojetin LD, Fowler FJ, Brown JA, Schnaier JA, Sweeny SF. The use of cognitive testing to develop and evaluate CAHPS 1.0 core survey items. Consumer Assessment of Health Plans Study. Med Care. 1999 Mar 1;37(3 Suppl):MS10-21.
Hays RD, Shaul JA, Williams VS, Lubalin JS, Harris-Kojetin LD, Sweeny SF, Cleary PD. Psychometric properties of the CAHPS 1.0 survey measures. Consumer Assessment of Health Plans Study. Med Care. 1999 Mar 1;37(3 Suppl):MS22-31.
Schnaier JA, Sweeny SF, Williams VS, Kosiak B, Lubalin JS, Hays RD, Harris-Kojetin LD. Special issues addressed in the CAHPS survey of Medicare managed care beneficiaries. Consumer Assessment of Health Plans Study. Med Care. 1999 Mar 1;37(3 Suppl):MS69-78.
Perez-Gutthann S, Petri M, Hochberg MC. Comparison of two methods of classifying patients with systemic lupus erythematosus. J Rheumatol. 1991 Aug 1;18(8):1176-9.